CLINICAL TRIALS PROFILE FOR HYDROXYZINE
✉ Email this page to a colleague
All Clinical Trials for HYDROXYZINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00162786 ↗ | Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance | Terminated | J. Uriach and Company | Phase 4 | 2005-05-01 | The primary objective of this study is to measure and compare the acute effects of rupatadine 10 mg, relative to placebo and hydroxyzine 50 mg as an active control on healthy volunteers' performance on a standard over-the-road driving test and a car-following test. |
| NCT00202514 ↗ | Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms | Completed | Abbott | Phase 2/Phase 3 | 2004-09-01 | The purpose of this study is to test the safety and effectiveness of an extended release form of a medication called divalproex sodium (Depakote ER) for the treatment of people with alcohol dependence who have mood and/or anxiety symptoms. This medication has helped reduce symptoms of acute alcohol withdrawal as well as stabilize mood symptoms in bipolar disorder and other mental health disorders. This study will test the hypothesis that divalproex sodium will help reduce mood and anxiety symptoms during early abstinence from alcohol and in turn reduce relapse and craving for alcohol. |
| NCT00202514 ↗ | Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms | Completed | Seattle Institute for Biomedical and Clinical Research | Phase 2/Phase 3 | 2004-09-01 | The purpose of this study is to test the safety and effectiveness of an extended release form of a medication called divalproex sodium (Depakote ER) for the treatment of people with alcohol dependence who have mood and/or anxiety symptoms. This medication has helped reduce symptoms of acute alcohol withdrawal as well as stabilize mood symptoms in bipolar disorder and other mental health disorders. This study will test the hypothesis that divalproex sodium will help reduce mood and anxiety symptoms during early abstinence from alcohol and in turn reduce relapse and craving for alcohol. |
| NCT00262639 ↗ | Prometa Protocol for Alcohol Dependence | Completed | Medical University of South Carolina | Phase 2/Phase 3 | 2005-12-01 | This is a placebo controlled trial (some people receive active and some people receive inactive medication) to evaluate the effectiveness of a new protocol to treat alcohol dependence. Two main medications (plus ancillary non-placebo controlled medications) and their placebos (inactive drugs) will be utilized to treat both alcohol withdrawal, promote abstinence, and reduce drinking over approximately a six-week treatment period. All participants will meet criteria for Alcohol Dependence and be drinking heavily up until 72 hours prior to receiving the first study drug. They will be injected one drug (flumazenil or placebo) over a two day period and receive the second one (gabapentin or placebo) by mouth for 39 days. The main hypothesis is that this protocol will reduce early alcohol withdrawal symptoms and will reduce relapse to drinking and promote abstinence compared to the placebo (inactive) drug group. Secondary outcomes that will be evaluated include reduction in craving, improvement in sleep, brain activity and mood. |
| NCT00661674 ↗ | Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal | Completed | Stanford University | N/A | 2008-04-01 | Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. We are interested in knowing if a medication named Ondansetron can help ease or prevent symptoms associated with opioid withdrawal. We are also interested in knowing if a similar (but more potent FDA-approved drug, palonosetron) can more effectively treat withdrawal symptoms with or without combination with an antihistamine called hydroxyzine (vistaril). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HYDROXYZINE
Condition Name
Clinical Trial Locations for HYDROXYZINE
Trials by Country
Clinical Trial Progress for HYDROXYZINE
Clinical Trial Phase
Clinical Trial Sponsors for HYDROXYZINE
Sponsor Name
| Sponsor Name for HYDROXYZINE | |
| Sponsor | Trials |
| University Hospital, Clermont-Ferrand | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| Seattle Institute for Biomedical and Clinical Research | 1 |
| [disabled in preview] | 2 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
